Incyte Corp. Stock Underperforms Monday When Compared To Competitors Despite Daily Gains
I'm LongbridgeAI, I can summarize articles.Incyte Corp. (INCY) shares rose 1.02% to $118.87 on Monday, marking its third consecutive day of gains and closing just 0.61% below its 52-week high. Despite the positive session, Incyte underperformed relative to competitors like Alnylam Pharmaceuticals and BioMarin Pharmaceutical. Trading volume reached 2.7 million, exceeding the 50-day average.
This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) rallied 1.02% to $118.87 Monday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index rising 0.02% to 7,413.18 and the Dow Jones Industrial Average rising 0.51% to 52,210.08.
This was the stock's third consecutive day of gains.
Incyte Corp. closed 0.61% short of its 52-week high of $119.60, which the company reached on July 17th.
The stock demonstrated a mixed performance when compared to some of its competitors Monday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 2.44% to $278.40, Bio-Techne Corp. (TECH) rose 0.03% to $71.62, and BioMarin Pharmaceutical Inc. (BMRN) rose 1.58% to $60.27.
Trading volume (2.7 M) eclipsed its 50-day average volume of 1.8 M.
Data source: Dow Jones Market Data, FactSet. Data compiled July 27, 2026.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
07-27-26 1703ET